TriangleR-DXD (NCT06780098)
R-DXD trial for Lung Neoplasm (NCT06780098). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with stage IV squamous non-small-cell lung cancer that progressed after both checkpoint immunotherapy and platinum chemotherapy. Prior docetaxel is excluded.
The idea: compare antibody-drug conjugates with docetaxel chemotherapy. Raludotatug deruxtecan targets CDH6; ifinatamab deruxtecan targets B7-H3. Both carry DNA-damaging payloads to targeted cells. Randomized groups receive raludotatug, either of two ifinatamab doses, or docetaxel, by infusion every three weeks. Researchers compare tumor response and safety. Treatment continues until progression or discontinuation.
This phase 2 study plans 144 patients. Merck sponsors four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.